2018 Shaffer Research Grants

For information about Shaffer Grants and research reports prior to 2013, please contact Glaucoma Research Foundation.

Spacing: small

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013

Spacing: small
Monica M. Jablonski, Phd

Monica M. Jablonski, PhD

University of Tennessee Health Science Center
Funded by The Edward Joseph Daly Foundation
Project: Extended Release IOP-Lowering Formulation
Summary: Glaucoma is the leading cause of irreversible blindness in the world, which is projected to affect about 6.3 million Americans by 2050, and intraocular pressure (IOP) is a leading contributor to glaucoma.
Mary J. Kelley, Phd

Mary J. Kelley, PhD

Oregon Health & Sciences University
Funded by Dr. James and Elizabeth Wise
Project: Trabecular Meshwork Stem Cells and the Identification of the Laser Factor
Summary: A healthy normally functioning eye is dependent upon a certain number of cells for good vision.
David Krizaj, Phd

David Krizaj, PhD

University of Utah
Funded by The Dr. Miriam Yelsky Memorial Research Grant
Project: Regulation of Tensile Homeostasis in the Trabecular Meshwork
Summary: Given that pressure-lowering eye drops are by far the most common treatment for glaucoma it is astounding that we know so little about how the effects of pressure are sensed and transduced in the eye.
Yvonne Ou, Md

Yvonne Ou, MD

University of California, San Francisco
Funded by Roberta and Robert H. Feldman
Project: Ganglion Cell Dysfunction in Glaucoma
Summary: Glaucoma is an irreversible blinding disease in which the cells that comprise the optic nerve, the retinal ganglion cells (RGCs), are damaged and die.
Padmanabhan Pattabiraman, Phd

Padmanabhan Pattabiraman, PhD

Case Western Reserve University
Funded by The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research
Project: Anti-fibrogenic Matricellular Protein CCN1 as a Novel Therapeutic Target to Lower Intraocular Pressure
Summary: Critical barriers in the development of efficient IOP lowering therapies could be overcome if there were a better mechanistic understanding governing ECM homeostasis, TM stiffness and the pathobiological basis of altered ECM deposition in the aqueous humor outflow pathway leading to increased stiffness and outflow resistance.
Giuliano Scarcelli, Phd

Giuliano Scarcelli, PhD

University of Maryland
Funded by The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research
Project: Noncontact Mechanical Mapping of the Optical Nerve Head with Brillouin Microscopy
Summary: The mechanism by which elevated IOP levels induce degradation of the optical nerve head (ONH), the initial site of injury in glaucoma, is not yet understood but it is widely suspected that a main culprit is the lack of mechanical balance between IOP-induced strains and the stiffness of ONH and surrounding sclera.
Dorota Skowronska-Krawczyk, Phd

Dorota Skowronska-Krawczyk, PhD

University of California, San Diego
Funded by The R. David Sudarsky Charitable Testamentary Trust
Project: Eliminate to Protect
Summary: Glaucoma is a group of optic neuropathies characterized by slow, progressive loss of retinal ganglion cells (RGCs), degeneration of the optic nerve and, consequently, loss of vision.
Trent A. Watkins, Phd

Trent A. Watkins, PhD

Baylor College of Medicine
Funded by The Dr. Henry A. Sutro Family Grant for Research
Project: Elucidating the Dynamics of the Neuronal Stress Response in Driving the Death of Retinal Ganglion Cells
Summary: In this study, we have developed a new tool for understanding how the efforts of retinal neurons to repair themselves in glaucoma can ultimately contribute to their demise.